Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Malignant degeneration of fibrous dysplasia is rare. It occurs with similar frequency at all ages and in both sexes. It is more frequent in cases of polyostotic than in monostotic fibrous dysplasia. In cases of fibrous dysplasia that do show malignant degeneration it is common to find that a high level of alkaline phosphatase persists in the serum, even in adults. Previous radiotherapeutic treatment appears to me a predisposing factor. Osteosarcoma is the most frequent neoplasm, followed at some distance by fibrosarcoma and chondrosarcoma. The tumour is most often localised in the femur; it is not unusual to find it in the tibia, maxilla and mandible. The treatment and prognosis are the same as those of the involved malignant neoplasm.
Ital J Orthop Traumatol 1979 Dec
PMID:Malignant degeneration in fibrous dysplasia (presentation of 6 cases and review of the literature). 29 46

The cyclic chemotherapy scheme OS I/75 was tried in 6 patients with newly diagnosed osteosarcoma and in 3 patients with secondary metastases. The treatment consists of high dose methotrexate, followed by citrovorum-factor rescue, doxorubicine (Adriblastin) and cyclophosphamide (Endoxan). All 6 primary patients are in a continuous remission of 6+ to 21+ months (median 12+ months). The length of remission in the patients with metastases is 5.5+ and 8+ months. The haematological side effects led to an average prolongation of the cycle by 11 days in a planned cycle duration of 42 days. However, they were readily manageable. Among the other side effects two cases of Adriblastin myocardiopathy are remarkable which became apparent after methotrexate and ifosfamide. In order to improve possibilities for treatment regional centralisation of patient care and interdisciplinary and supraregional cooperation of treatment centres are necessary. A prospective treatment programme has been developed for the Federal Republic of Germany and Austria.
Dtsch Med Wochenschr 1977 Dec 16
PMID:[Chemotherapy of osteosarcoma (author's transl)]. 30 80

Several experimental data support the evidence that Osteogenic Sarcoma is a virus-originated neoplasm. Cytogenetic and immunological aspects of this neoplasm are examined by the Authors on the basis of the latest advances in this field, and in view of possible therapeutic applications.
Chir Ital 1978 Dec
PMID:[Current views on pathology and new therapeutic perspective. I: Immunological aspects of the neoplasm (author's transl)]. 31 55

Two cases of osteosarcoma are described arising in patients who had undergone angiography with Thorotrast during childhood. In both patients, there was radiographic and pathologic evidence of radioactive thorium dioxide deposition in bone as well as throughout the reticuloendothelial system. Thorotrast deposits were demonstrated in the immediate vicinity of the primary tumors by both histology and autoradiography. Previous cases of osteosarcoma associated with Thorotrast administration from the literature are cited, and possible causal relationships are discussed between thorium retention in bone and neoplastic transformation by chronic radiation.
Cancer 1978 Dec
PMID:Osteosarcoma associated with Thorotrast administration: report of two cases and literature review. 36 15

The authors review recent studies and trials concerning the treatment of osteosarcoma, with special attention to current trends in immunology, radiology, surgery, and chemotherapy. Progress in immunobiological research seems to promise interesting practical developments; even today, however, modern chemotherapy combined with suitable ablative surgery affords a remarkably better prognosis for this malignancy.
Chir Ital 1978 Dec
PMID:[Osteosarcoma: current views on pathology and new therapeutic perspectives. II: Criteria of prognosis and treatment (author's transl)]. 38 Aug 33

An osteosarcoma developed near the right lesser trochanter of a 55-year-old woman. The neoplasm fulfilled the generally accepted criteria for a Thorotrast related malignancy. Strengthening this relationship was the occurrence of the tumor in an unusual location and uncommon age group. Thorium was confirmed both in the tumor and in bone marrow histiocytes by its characteristic x-ray spectrum. Including this case only twelve Thorotrast-associated neoplasms of bone have been reported. The mean latency period after Thorotrast administration was 26 years. Regression analysis revealed that latency period and Thorotrast dose are inversely related. All tumors were reported to be sarcomas. Six osteosarcomas, one fibrosarcoma, one chondrosarcoma, and one undifferentiated sarcoma were proven histologically. All patients, for whom follow-up was given, had died of the tumor. The reasons behind the low frequency of reported Thorotrast-associated bone malignancies may be the low concentration of 232Th and radioactive daughters in bone, long latency period or the general lack of knowledge concerning the possible relationship between Thorotrast and bone tumors. Statistical association between Thorotrast injection and bone sarcoma is shown. The criteria for the diagnosis of Thorotrastosis are discussed as well as the long term deleterious effects. The distribution of Thorotrast within the body is discussed as well as the associated radiographic changes.
Cancer 1979 Dec
PMID:Thorotrast-associated sarcoma of bone: A case report and review of the literature. 38 8

A 13-year-old girl with osteosarcoma and pulmonary metastases developed life-threatening renal toxicity, encephalopathy, and bone marrow failure following high dose methotrexate therapy. After successful treatment, high dose methotrexate therapy was continued without further problems. Recommendations for the prevention and the current management of methotrexate toxicity are discussed.
Onkologie 1979 Dec
PMID:[(Management of acute toxicity after high dose methotrexate therapy)]. 39 13

Arteriography was carried out in 64 cases of pathologically confirmed osteosarcoma to evaluate the angiographic features of this lesion. This investigation proved that a variety of angioarchitectures exist in osteosarcomas, mainly related to the histologic type of tissue as well as the degree of differentiation of a tumor. Fibroblastic and chondroblastic osteosarcomas proved to be less vascular than the osteoblastic type, while the most differentiated tumor appeared to be the least vascular. This technique proved useful in choosing the proper site, or sites, for biopsy as well as for determining the intra- and extraosseous extension of the tumor. Instances were also encountered in which it was of assistance in differentiating osteosarcoma from pathologically similar bone lesions.
AJR Am J Roentgenol 1977 Dec
PMID:Angiographic features of osteosarcoma. 41 62

Eleven patients with measurable subcutaneous or pulmonary metastases were selected for a study of the effectiveness of the radiosensitizer misonidazole (MIS). Evaluable data were obtained in 6 patients and radiosensitization demonstrated in 5. Patients were irradiated either before or after MIS, and each patient acted as his own control. Response to treatment in 5 cases was assessed in terms of growth delay, and radiation doses were selected in expectation of enhancement ratios of 1.2 to 1.5. In 1 case evidence of sensitization was obtained from differential tumour clearance from 2 areas of skin irradiated before or after MIS. Results in 4/5 growth-delay studies indicated enhancement ratios ranging from 1.1 to greater than 1.5. An enhancement ratio of 1.3 was measured in a case of squamous carcinoma treated by a 10-fraction course of irradiation. Evidence of sensitization was obtained in breast carcinoma, osteosarcoma, leiomyosarcoma, prostatic carcinoma and synoviosarcoma. The results of this study support the view that MIS may improve the radiotherapeutic management of a wide range of tumours, although more extensive data are required to identify those categories of disease in which greatest benefit will be obtained, and to indicate the optimum radiation schedule.
Br J Cancer 1979 Dec
PMID:The quantitative response of human tumours to radiation and misonidazole. 52 30

A rare case of malignant chondromyxoid fibroma developed in the scapula of a woman who was treated with interscapulothoracic resection. When a biopsy specimen was submitted for study, difficulty was encountered in establishing the histologic diagnosis. A large dose of radiation was given before surgery, based on an original biopsy diagnosis of osteosarcoma; in retrospect, preoperative irradiation probably was contraindicated. Two years and four months after surgery, the patient was working with no evidence of recurrence or metastasis.
South Med J 1977 Dec
PMID:Malignant chondromyxoid fibroma of the scapula. 59 3


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>